Search results
Showing 16 to 30 of 7996 results
Risankizumab for treating moderately to severely active ulcerative colitis (TA998)
Evidence-based recommendations on risankizumab (Skyrizi) for treating moderately to severely active ulcerative colitis in adults.
Benefits of new Alzheimer's treatment lecanemab are too small to justify the cost to the NHS
Our draft recommendation follows analysis of clinical trial evidence and reviewing the benefits of slowing disease progression, with the cost of treatment.
Phrenic nerve pacing for congenital central hypoventilation syndrome (IPG790)
Evidence-based recommendations on phrenic nerve pacing for congenital central hypoventilation syndrome. This involves direct stimulation of the phrenic nerve, to produce the inhalation phrase of breathing.
View recommendations for IPG790Show all sections
Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury (IPG792)
Evidence-based recommendations on phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury. This involves stimulating the phrenic nerve to make the diaphragm contract, helping people to breathe without a ventilator.
View recommendations for IPG792Show all sections
This indicator covers breast cancer mortality rates (female). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG04
This indicator covers the proportion of women aged 53 to 70 years whose record shows a breast screening test has been performed within the last 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG84
Caval valve implantation for tricuspid regurgitation (IPG791)
Evidence-based recommendations on caval valve implantation for tricuspid regurgitation in adults. This involves implanting valves into 1 or both caval veins without disturbing the tricuspid valve.
View recommendations for IPG791Show all sections
No evidence to support the price variation in heart valves used by the NHS
Draft guidance issued today (9 August) states that the variation in price the NHS is paying for valves used in keyhole heart procedures is not supported by reliable evidence.
Cardiovascular disease prevention: risk assessment (general population) (IND269)
This indicator covers the percentage of people aged 45 to 84 years who have a recorded cardiovascular disease (CVD) risk assessment score in the preceding 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Smoking: cessation success in people with bipolar, schizophrenia and other psychoses (IND271)
This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder and other psychoses recorded as current smokers in the previous 13 to 48 months, who were recorded as ex-smokers in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Cardiovascular disease prevention: risk assessment (modifiable risk factors) (IND270)
This indicator covers the percentage of people aged 43 to 84 years with a modifiable risk factor who have a recorded cardiovascular disease (CVD) risk assessment score in the preceding 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Relugolix for treating hormone-sensitive prostate cancer (TA995)
Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.
Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)
Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.
Thousands could benefit from new option for treating symptoms of uterine fibroids
As many as 30,000 adults could benefit from a new treatment for moderate to severe symptoms of uterine fibroids after we published final guidance today (14 August 2024) recommending linzagolix.
This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.